USVI Response Measures

1. Prevent, delay, and mitigate transmission:
   Develop screening at ports of entry; provide best practices and guidance to organizations to reduce transmission; develop strategies for vulnerable populations.

2. Conduct surveillance:
   Inform the response based on epidemiologic data; liaise with healthcare sector to identify cases and define clinical and transmission characteristics; operate epi hotline; track persons under investigation; perform contact tracing of cases; conduct follow-up sampling of cases; coordinate with lab.

3. Provide public health & safety messaging:
   Develop communication strategy; build capacity with partners; provide daily report.

4. Provide medical guidance:
   Provide Infection Prevention and Control guidance related to healthcare personnel and health systems; provide guidance to clinicians on treatment and management of patients.

5. Conduct lab testing:
   Build laboratory testing capacity for VIDOH; explore external lab capacity; manage specimen collection and supplies.

6. Coordinate medical surge capacity:
   Assess resource needs and inventory resources (equipment, staff); develop a health and medical staffing strategy; prepare resource requests for material aid and staff (federal partner, EMAC, etc); develop resource management, utilization, and prioritization plan.

Testing Summary

<table>
<thead>
<tr>
<th></th>
<th>27-Jun</th>
<th>26-Jun</th>
<th>Change since 26-Jun</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total tested</td>
<td>2858</td>
<td>2858</td>
<td>0</td>
</tr>
<tr>
<td>Tested positive</td>
<td>81</td>
<td>81</td>
<td>0</td>
</tr>
<tr>
<td>Tested negative</td>
<td>2773</td>
<td>2746</td>
<td>27</td>
</tr>
<tr>
<td>Pending tests</td>
<td>4</td>
<td>31</td>
<td>-27</td>
</tr>
</tbody>
</table>

Test result among males and females

- Males: n=32
- Females: n=1337
- Unknown: n = 236

Test result by age group

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Test positive</th>
<th>Test negative</th>
<th>Test positive percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-17</td>
<td>81</td>
<td>2746</td>
<td>2%</td>
</tr>
<tr>
<td>18-49</td>
<td>32</td>
<td>1337</td>
<td>3%</td>
</tr>
<tr>
<td>50-64</td>
<td>1200</td>
<td>0</td>
<td>4%</td>
</tr>
<tr>
<td>65+</td>
<td>0</td>
<td>4</td>
<td>2%</td>
</tr>
</tbody>
</table>

Sample collection dates of persons under investigation for COVID-19 in the U.S. Virgin Islands

Illnesses that started during this time may not yet be reported.
Current status of cases
- Active: 4
- Recovered: 71
- Fatality: 6

Risk factors for transmission
- Community transmission: 22
- Close contact: 30
- Travel: 29
- Under investigation: 0

Clinical symptoms
- Cough: 52 (64%)
- Fever*: 47 (58%)
- Shortness of breath: 28 (35%)

*Subjective fever or measured temp ≥100.4°F

COVID-19 Confirmed Cases (37)
- St. Croix
- U.S. Virgin Islands

COVID-19 Confirmed Cases (40)
- St. Thomas
- U.S. Virgin Islands

COVID-19 Confirmed Cases (4)
- St. John
- U.S. Virgin Islands

As of June 25, 2020

*ALL DATA ARE PROVISIONAL*